Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KARS1 | Q15046 | 13/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225041 | 0.89 | KARS1 (0.53) | KARS1SYKMAP3K12 | |
| SCHEMBL14673910 | 0.86 | KARS1 (0.40) | KARS1SYKCCNT1CDK4CCND1 | |
| SCHEMBL14673612 | 0.84 | KARS1 (0.52) | KARS1SYKCCNT1CDK4CCND1 | |
| SCHEMBL14673822 | 0.83 | KARS1 (0.42) | KARS1SYKCCNT1CDK4CCND1 | |
| SCHEMBL13823522 | 0.83 | CCNT1 (0.41) | KARS1SYKCCNT1CDK4CCND1 | |
| SCHEMBL2225729 | 0.83 | SYK (0.48) | KARS1SYKCCNT1CDK4CCND1 | |
| SCHEMBL16519334 | 0.82 | CDK4 (0.38) | KARS1SYKCCNT1CDK4CCND1 | |
| SCHEMBL2286328 | 0.81 | CCNT1 (0.39) | KARS1SYKCCNT1CDK4CCND1 | |
| SCHEMBL2227650 | 0.81 | AOC3 (0.37) | KARS1SYKCCNT1CDK4CCND1 | |
| SCHEMBL14673663 | 0.79 | KDR (0.40) | KARS1SYKCCNT1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523952-B1 | OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-03-04 | — | — | EP | claimed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | claimed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | claimed |
| EP-2523952-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB Science (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086085-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2011-07-21 | — | — | WO | claimed |
| EP-2523952-B1 | OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-03-04 | — | — | EP | disclosed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | disclosed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | disclosed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SYK, LTK, MERTK | KARS1 1099/4885SYK 1/4885CCNT1 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.